Self‐reported distress · children aged 3‐18 years with mixed medical (acute or chronic illness) or generally healthy undergoing immunization, intravenous…
1 finding from 1 review
Observer‐reported pain · children aged 3‐18 years with mixed medical (acute or chronic illness) or generally healthy undergoing immunization, intravenous…
1 finding from 1 review
Intervention not reported
Primary outcome 1: participant‐ or parent‐rated symptoms of eczema (SCORAD part C) at the end of active treatment Visual analogue scale for itch and sleep disturbance ranging from 0 to 10 for each symptom and combined ranging from 0 to 20. The hig... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Primary outcome 1: participant‐ or parent‐rated global change in eczema symptoms at the end of active treatment (binary outcome) Change in risk for worsened/unchanged eczema Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
The intervention showed no clear difference in primary outcome 1: participant‐ or parent‐rated global change in… (low certainty).
1 finding from 1 review
Intervention not reported
Primary outcome 2: participant‐ or parent‐rated participant quality of life score at the end of active treatment Scales used: DLQI, IDQoL, Skindex‐29, CDLQI. On those scales, the higher the score, the more severely the quality of life is affected ... · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Primary outcome 2: participant‐ or parent‐rated family quality of life score at the end of active treatment Scale used: DFI, FDLQI. On those scales, the higher the score, the more severely the quality of life is affected Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Secondary outcome 4: global eczema severity score (total SCORAD) at the end of active treatment (Investigator‐rated eczema severity) Scale used: total SCORAD ranging from 0 to 103. The higher the score, the more severe the disease Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
1 finding from 1 review
Intervention not reported
Secondary outcome 6: adverse events (gastrointestinal symptoms) during active treatment Duration of · male and female patients 0 to 55 years of age with physician‐diagnosed eczema
The intervention showed no clear difference in secondary outcome 6: adverse events (gastrointestinal symptoms)… (low certainty).
1 finding from 1 review
Intervention not reported
Primary outcomes · children aged 4 to 12 years with CAS of unknown cause
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Accuracy of production on treated items Measured by: counting the number of real words produced correctly (/x) · children aged 4 to 12 years with CAS of unknown cause
1 finding from 1 review
Intervention not reported
Accuracy of production on non‐treated items Measured by: counting the number of real words produced correctly (/x) · children aged 4 to 12 years with CAS of unknown cause
1 finding from 1 review
Intervention not reported
Secondary outcomes · children aged 4 to 12 years with CAS of unknown cause
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Speech production consistency Measured by: calculating the number of inconsistent productions of 25 words produced 3 times using the DEAP inconsistency subtestb · children aged 4 to 12 years with CAS of unknown cause
1 finding from 1 review
Intervention not reported
Accuracy of connected speech Measured by: counting the number of correct imitations of 3 word phrases (/x) · children aged 4 to 12 years with CAS of unknown cause
1 finding from 1 review
Change in Ejection fraction (%) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Change in cardiac function (change in peak systolic radial strain in LV lateral wall segments) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Change in cardiac function (change in systolic radial strain rate LV inferolateral wall) · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review
Size of metabolically abnormal areas of myocardium · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Improvements in quality of life measures · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · boys (aged 8 to 16 years old) with subclinical cardiomyopathy in DMD
1 finding from 1 review